Table 1.
Demographics, risk factors, and outcome events for each cohort
| Total partici-pants | Taking oral anticoagu-lants | Transient ischaemic attack | Mean age (SD), years | Proportion women | Hyper-tension | Atrial fibrillation | Previous stroke | Ischaemic heart disease | Any cerebral microbleed | Susceptibility-weighted imaging | Median follow-up, days (IQR) | Patients with composite events | Participants with intracranial haemorrhage events | Participants with ischaemic stroke events | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CROMIS-227 | 1490 | 1436 (96%) | 238 (16%) | 76 (10) | 631 (42%) | 930 (63%) | 1490 (100%) | 148 (10%) | 243 (16%) | 311 (21%) | 0 | 774 (705–974) | 70 (5%) | 14 (1%) | 56 (4%) |
| HBS | 660 | 114 (17%) | 60 (9%) | 69 (15) | 289 (44%) | 498 (75%) | 194 (29%) | 156 (24%) | 138 (21%) | 98 (15%) | 2 (<1%) | 90 (90–90) | 4 (1%) | 0 | 4 (1%) |
| IPAAC-Warfarin35 | 182 | 173 (95%) | 27 (15%) | 73 (9) | 84 (46%) | 158 (87%) | 179 (98%) | 36 (20%) | 17 (9%) | 68 (37%) | 182 (100%) | 738 (191–812) | 7 (4%) | 1 (1%) | 6 (3%) |
| Bern36 | 392 | 74 (19%) | 0 | 68 (14) | 169 (43%) | 249 (64%) | 142 (46%) | 59 (15%) | 69 (18%) | 90 (23%) | 392 (100%) | 93 (5–106) | 16 (4%) | 0 | 16 (4%) |
| CU-STRIDE37 | 536 | 24 (4%) | 81 (15%) | 67 (11) | 227 (42%) | 373 (70%) | 38 (7%) | 80 (15%) | 35 (7%) | 124 (23%) | 238 (44%) | 524 (472–557) | 17 (3%) | 2 (<1%) | 15 (3%) |
| TABASCO38 | 436 | 33 (8%) | 213 (28%) | 67 (9) | 184 (43%) | 250 (59%) | 33 (8%) | 0 | 60 (14%) | 64 (15%) | 0 | 1825 (1164–1825) | 57 (13%) | 0 | 57 (13%) |
| Graz | 460 | 78 (17%) | 48 (10%) | 67 (13) | 179 (39%) | 359 (78%) | 115 (25%) | 102 (22%) | 95 (21%) | 88 (19%) | 0 | 117 (87–973) | 65 (14%) | 13 (3%) | 54 (12%) |
| PERFORM-MRI39 | 1056 | 0 | 127 (12%) | 68 (8) | 370 (35%) | 887 (84%) | 16 (2%) | 120 (11%) | 69 (7%) | 381 (36%) | 0 | 774 (701–1042) | 104 (10%) | 10 (1%) | 94 (9%) |
| PARISK40 | 228 | 0 | 127 (56%) | 71 (9) | 67 (29%) | 156 (68%) | 0 | 66 (29%) | 50 (22%) | 61 (27%) | 0 | 786 (757–819) | 10 (4%) | 0 | 10 (4%) |
| SAMURAI NVAF41 | 1103 | 1039 (94%) | 45 (4%) | 78 (10) | 480 (44%) | 1027 (93%) | 1103 (100%) | 246 (22%) | 101 (9%) | 265 (24%) | 817 (74%) | 723 (758–818) | 82 (7%) | 10 (1%) | 72 (7%) |
| RUNDMC42 | 179 | 19 (11%) | 89 (50%) | 65 (9) | 63 (35%) | 145 (81%) | 18 (10%) | 47 (26%) | 31 (17%) | 35 (20%) | 0 | 1825 (1825–1825) | 25 (14%) | 2 (1%) | 23 (13%) |
| Wuerzburg | 358 | 122 (34%) | 77 (22%) | 71 (13) | 158 (44%) | 287 (80%) | 105 (29%) | 91 (25%) | 38 (11%) | 87 (24%) | 160 (45%) | 95 (89–103) | 22 (6%) | 1 (<1%) | 21 (6%) |
| Monash Stroke43 | 359 | 356 (99%) | 52 (15%) | 75 (11) | 173 (48%) | 285 (79%) | 359 (100%) | 101 (28%) | 122 (34%) | 154 (43%) | 339 (94%) | 530 (280–898) | 14 (4%) | 7 (2%) | 9 (3%) |
| Basel TIA18 | 192 | 33 (17%) | 192 (100%) | 69 (13) | 73 (38%) | 137 (71%) | 26 (14%) | 13 (7%) | 38 (20%) | 21 (11%) | 0 | 90 (90–90) | 26 (14%) | 0 | 26 (14%) |
| Yonsei44 | 504 | 487 (97%) | 28 (6%) | 70 (11) | 288 (57%) | 392 (78%) | 504 (100%) | 101 (20%) | 109 (22%) | 155 (31%) | 0 | 849 (393–1398) | 56 (11%) | 7 (1%) | 49 (10%) |
| SNUBH Stroke Cohort45, 46 | 3355 | 625 (19%) | 368 (11%) | 67 (13) | 1347 (40%) | 2324 (69%) | 630 (19%) | 487 (15%) | 284 (8%) | 1166 (35%) | 1 (<1%) | 355 (340–365) | 172 (5%) | NA | NA |
| BIOSTROKE/TIA47 | 260 | 73 (28%) | 160 (62%) | 68 (13) | 95 (37%) | 150 (59%) | 77 (31%) | 21 (8%) | 57 (22%) | 24 (9%) | 0 | 90 (90–365) | 14 (5%) | 0 | 14 (5%) |
| Kushiro City48 | 784 | 63 (8%) | 0 | 72 (11) | 330 (42%) | 498 (64%) | 104 (13%) | 142 (18%) | 89 (11%) | 320 (41%) | 0 | 1008 (105–1825) | 139 (18%) | 22 (3%) | 119 (15%) |
| Soo49 | 81 | 81 (100%) | 16 (20%) | 72 (9) | 40 (49%) | 56 (69%) | 81 (100%) | 25 (31%) | 8 (10%) | 24 (30%) | 71 (88%) | 737 (641–794) | 8 (10%) | 3 (4%) | 5 (6%) |
| CASPER50 | 135 | 18 (13%) | 0 | 66 (11) | 39 (29%) | 96 (71%) | 13 (10%) | 10 (7%) | 29 (21%) | 79 (59%) | 135 (100%) | 453 (444–465) | 3 (2%) | 0 | 3 (2%) |
| HERO51 | 937 | 933 (>99%) | 122 (13%) | 78 (7) | 488 (52%) | 694 (74%) | 468 (50%)* | 248 (27%) | 146 (16%) | 248 (26%) | 0 | 737 (641–794) | 49 (5%) | 18 (2%) | 32 (3%) |
| HAGAKURE | 426 | 157 (37%) | 35 (8%) | 74 (13) | 174 (41%) | 320 (76%) | 135 (32%) | 76 (18%) | 45 (11%) | 158 (37%) | 39 (9%) | 748 (350–1040) | 34 (8%) | 9 (2%) | 25 (6%) |
| Leuven14 | 487 | 133 (27%) | 133 (27%) | 72 (9) | 192 (39%) | 313 (64%) | 103 (21%) | 61 (13%) | 112 (23%) | 129 (26%) | 0 | 804 (686–968) | 36 (7%) | 4 (1%) | 32 (7%) |
| NOACISP | 306 | 286 (93%) | 30 (10%) | 73 (19) | 139 (45%) | 240 (79%) | 306 (100%) | 60 (20%) | 83 (27%) | 87 (28%) | 300 (98%) | 735 (417–836) | 28 (9%) | 10 (3%) | 19 (6%) |
| Min Lou52 | 126 | 14 (11%) | 0 | 65 (13) | 46 (37%) | 94 (75%) | 25 (20%) | 18 (14%) | 4 (3%) | 42 (33%) | 126 (100%) | 92 (87–218) | 2 (2%) | 0 | 2 (2%) |
| MICRO21 | 397 | 40 (10%) | 362 (91%) | 65 (12) | 165 (42%) | 218 (55%) | 30 (8%) | 35 (9%) | 24 (6%) | 72 (18%) | 0 | 1212 (579–1825) | 30 (8%) | 11 (3%) | 21 (5%) |
| Orken53 | 454 | 454 (100%) | 20 (4%) | 72 (12) | 233 (51%) | 258 (79%) | 296 (65%) | 123 (27%) | 79 (32%)† | 134 (30%) | 250 (55%) | 575 (228–1825) | 11 (2%) | 3 (1%) | 8 (2%) |
| CATCH54 | 416 | 67 (16%) | 173 (42%) | 67 (14) | 164 (39%) | 226 (54%) | 27 (6%) | 0 | NA | 65 (16%) | 0 | 88 (80–100) | 14 (3%) | 1 (<1%) | 13 (3%) |
| MSS255 | 263 | 24 (9%) | 0 | 67 (12) | 109 (41%) | 190 (72%) | 25 (10%) | 32 (12%) | 53 (20%) | 44 (17%) | 251 (95%) | 368 (253–403) | 31 (12%) | 0 | 31 (12%) |
| Sainte-Anne (Paris) | 385 | 302 (78%) | 0 | 80 (11) | 204 (53%) | 277 (72%) | 358 (100%) | 61 (16%) | 72 (19%) | 99 (26%) | 0 | 440 (163–733) | 25 (6%) | 5 (1%) | 23 (6%) |
| STROKDEM | 181 | 48 (27%) | 0 | 64 (13) | 69 (38%) | 100 (55%) | 12 (7%) | 20 (11%) | 17 (9%) | 24 (13%) | 0 | 1150 (420–1820) | 17 (9%) | 0 | 17 (9%) |
| Singapore (Chen) | 45 | 15 (33%) | 0 | 67 (10) | 13 (29%) | 34 (76%) | 11 (24%) | 3 (7%) | 4 (9%) | 25 (56%) | 45 (100%) | 1057 (703–1199) | 6 (13%) | 0 | 6 (13%) |
| FUTURE Study | 19 | 0 | 7 (37%) | 44 (6) | 10 (53%) | 8 (42%) | 0 | 0 | 0 | 1 (5%) | 19 (100%) | 164 (131–242) | 4 (21%) | 0 | 4 (21%) |
| Heidelberg56 | 650 | 119 (18%) | 109 (17%) | 64 (14) | 240 (37%) | 496 (76%) | 115 (18%) | 107 (17%) | NA | 155 (24%) | 650 (100%) | 1534 (1271–1825) | 34 (5%) | 4 (1%) | 30 (5%) |
| NNI | 184 | 32 (17%) | 0 | 58 (11) | 57 (31%) | 143 (78%) | 28 (15%) | 27 (15%) | NA | 50 (27%) | 0 | 251 (86–477) | 0 | 0 | 0 |
| OXVASC29 | 1080 | 118 (11%) | 572 (52%) | 68 (14) | 514 (48%) | 588 (55%) | 167 (15%) | 201 (19%) | 146 (13%) | 157 (15%) | 0 | 1271 (681–1825) | 90 (8%) | 11 (1%) | 79 (7%) |
| HKU29 | 1003 | 104 (10%) | 0 | 69 (12) | 402 (40%) | 657 (66%) | 130 (13%) | 116 (12%) | 92 (9%) | 450 (45%) | 1003 (100%) | 1005 (599–1549) | 112 (11%) | 20 (2%) | 92 (9%) |
| SIGNaL | 213 | 43 (20%) | 22 (10%) | 72 (14) | 88 (41%) | 152 (71%) | 67 (32%) | 60 (28%) | 49 (23%) | 94 (44%) | 144 (68%) | 225 (202–249) | 27 (13%) | 1 (<1%) | 26 (12%) |
| Total | 20 322 | 7737/20 319 (38%) | 3443/20 311 (17%) | 70 (13) | 8593/20 314 (42%) | 14 365/20 271 (71%) | 7557/20 207 (37%) | 3299/20 290 (16%) | 2608/18 842 (14%) | 5649/20 322 (28%) | 5164/20 284 (25%) | 534 (243–928) | 1461/20 322 (7%) | 189/16 967 (1%) | 1113/16 967 (7%) |
Data are n (%) or n/N (%) unless otherwise stated. Studies without references are unpublished. FUTURE study=Follow-Up of Transient ischemic attack and stroke patients and Unelucidated Risk factor Evaluation study. HAGAKURE=Hypertension, Amyloid, and aGe Associated Kaleidoscopic brain lesions on CT/MRI Undertaken with stroke REgistry. HBS=Heart Brain Interactions Study. NNI=National Neuroscience Institute, Singapore. NOACISP=Novel Oral Anticoagulants in Stroke Patients, Basel; NCT02353585. SIGNaL=Stroke Investigation in North and Central London. STROKDEM=Study of Factors Influencing Post-stroke Dementia.
*
Denominator for this result is 932.
†
Denominator for this result is 250.